Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Webinar presenters Kyle C. Strickland, MD, PhD, Director of Medical Affairs, Labcorp, and Tricia Numan, MD, Gynecologic Pathologist and Director of the Women’s Health Initiative at Roswell Park Comprehensive Cancer Center, discuss the biology and clinical significance of homologous recombination deficiency (HRD) in ovarian cancer.
Webinar presenter Josef Rüschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos,
Senior Consultant of Discovery Life Sciences, Kassel, Germany. Hear from Dr. Rüschoff, an expert in HER2 IHC, whose work has contributed to current scoring guidelines.
Webinar presenters Shyam M. Sivasankar, MD, FAAP, FACEP, Associate Trauma Medical Director & Assistant Professor, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, and Dan Feinstein, MD, FACP, Director of Pulmonary Critical Care Medicine, Triad Region; System-wide Director, TeleICU & Co-Director, Sepsis, Novant Health, team up for this session bringing together two physicians—one representing inpatient and critical care from a large health system, and the other offering a perspective on urgent and near-patient care—to share how syndromic polymerase chain reaction (PCR) testing informs real-world patient management.
Webinar presenters Wendy Vitek, MD, Board-certified Reproductive Endocrinologist, Boston IVF’s Syracuse, NY Fertility Center, and Shirley Li, MD, PhD, Associate Professor-Clinical, Department of Pathology; Director of Clinical Pathology Services and Co-Director of the Clinical Chemistry & Toxicology Laboratory, The Ohio State University, explore Anti-Müllerian Hormone (AMH) from both analytical and clinical perspectives.
Webinar presenters Liron Pantanowitz, MD, PhD, MHA, Chair and Maud Menten Professor of Pathology, UPMC/University of Pittsburgh UPMC Shadyside Hospital, and Richard Lozano, MD, President, P&C Labs, LLC. and Vice President, Chipps, Caffrey, Dubilier, and PSC, discuss their experience with the Genius Digital Diagnostics System and data leveraging digital cytology for cervical cancer screening.
Webinar presenters Wei Zhang, MD, PhD, Medical Director of Molecular Pathology (Solid Tumor), University of Kansas, and Tejas Patil, MD, Thoracic Medical Oncologist, UCHealth, University of Colorado, discuss RNA testing practices and pathogenic gene fusions testing, with special focus on NRG1 fusions testing and management.
Webinar presenters David Chi, PhD, Director of Oncology Product Management, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix, Inc., and Bence Sipos, MD, Molecular Pathology, Baden-Württemberg, Stuttgart, Germany, discusses the rapidly evolving field of precision oncology, the increasing availability of targeted treatments offers renewed hope to patients.
Webinar presenters Emilie Lalonde, PhD, FACMG, Molecular Geneticist and Cytogeneticist, Molecular Diagnostics Division, PaLM, London Health Sciences Centre and St. Joseph’s Health Care, Assistant Professor, Pathology and Laboratory Medicine, Western University, and Cheryl A. Mather, MD Medical Director, Molecular Pathology (North Sector), Alberta Precision Laboratories, Assistant Clinical Professor, Department of Laboratory Medicine & Pathology, University of Alberta, discuss how amplicon-based NGS panels meet biomarker testing guidelines in practice including routine diagnostics, expanded workup, and copy number variation (CNV) detection.
Webinar presenter Karen Raraigh, MGC, CGCD, Assistant Professor of Genetic Medicine at Johns Hopkins University, discusses how expanded genetic testing is playing an increasingly vital role in the management of Cystic Fibrosis (CF), helping to elevate the standard of care.
Thursday, March 5, 2026
11:00 AM–12:00 PM ET
Learn how EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing the future of diagnostics, prognostics, and targeted therapies and how these revolutionary assays provide comprehensive genomic data that reveals mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.
Webinar presenters David Gonzalez, PhD, FRCPath, CEO, Univ8 Genomics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
